Latest Conference Articles

June 12th 2019, 7:00pm

ASCO Annual Meeting

Treatment with lisocabtagene maraleucel, also known as liso-cel, demonstrated clinical activity and appeared tolerable among patients with relapsed/refractory mantle cell lymphoma.

June 12th 2019, 5:00pm

ASCO Annual Meeting

Sue Friedman, founder and executive director of FORCE, discussed how a breast cancer diagnosis at age 33 and a family history of cancer led to the creation of Facing Our Risk of Cancer Empowered.

June 11th 2019, 5:49pm

ASCO Annual Meeting

Andrea Wilson, president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association, spoke with CURE® at the 2019 ASCO meeting about the loss of her sister and how it inspired her to found Blue Faery.

June 11th 2019, 12:09am

ASCO Annual Meeting

Jennifer King, from the GO2 Foundation for Lung Cancer, discussed what patients can do to help address the stigma associated with lung cancer.

June 7th 2019, 8:00pm

ASCO Annual Meeting

Researchers adapted a screening tool to help treat the whole person during cancer care.

June 7th 2019, 5:36pm

ASCO Annual Meeting

A practice improvement project at the Mayo Clinic helped to increase attention to family health history and identify those at risk for cancer.

June 6th 2019, 6:51pm

ASCO Annual Meeting

The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.

June 4th 2019, 10:32pm

ASCO Annual Meeting

The Food and Drug Administration revealed its pilot program, designed to assist oncologists and patients requesting access to unapproved therapies in the cancer space.

June 3rd 2019, 8:54pm

ASCO Annual Meeting

After progressing on prior therapy, 44% of patients with locally advanced or metastatic urothelial cancer who were treated with enfortumab vedotin demonstrated a response to treatment, according to phase 2 study findings.

June 3rd 2019, 5:42pm

ASCO Annual Meeting

The addition of Kisqali to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced HR-positive/HER2-negative breast cancer compared with endocrine therapy alone.

June 3rd 2019, 5:36pm

ASCO Annual Meeting

The phase 3 POLO trial is the first randomized study to establish a biomarker-driven approach in the treatment of metastatic pancreatic cancer.

May 23rd 2019, 8:31pm

ASCO Annual Meeting

Two oncology dietitians weigh in on the results of a recent study that show a low-fat diet rich in fruits, vegetables and grains can reduce the risk of dying from breast cancer.

May 20th 2019, 11:41pm

ASCO Annual Meeting

Using Revlimid as a preventative treatment for smoldering multiple myeloma significantly reduced the risk for the precursor disease to progress into cancer, compared with just observation.

October 22nd 2018, 10:55pm

FORCE Conference

Although there is never the perfect time to have a risk-related discussion with a child, one clinical psychologist explains ways in which parents can approach the difficult topic.

October 22nd 2018, 12:00am

FORCE Conference

To combat the psychological effects from a lymphedema diagnosis, patients need to be equipped with the knowledge and understanding of what the condition is and how it is treated.

October 21st 2018, 4:00pm

FORCE Conference

Eva Moon shares nine habits for keeping a sense of humor when the going gets rough.

October 21st 2018, 1:00am

FORCE Conference

One expert shares advice for opening the line of communication between patients and health care providers, as well as their partners.

October 20th 2018, 10:11pm

FORCE Conference

One family shares their experience with the discovery of a BRCA mutation, and how they discussed it among one another.

October 20th 2018, 8:58pm

FORCE Conference

Exercise and nutrition are essential to improving a variety of facets revolving around the continuum of cancer — from prevention to diagnosis and treatment to survivorship care.

October 20th 2018, 4:31am

FORCE Conference

Although individuals may have concerns about enrolling in a study, their involvement may lead to new discoveries.

October 20th 2018, 4:05am

FORCE Conference

A genetic counselor discussed the various hereditary breast and ovarian cancer syndrome-associated cancers among men and how to manage them at the FORCE Annual Meeting.

October 19th 2018, 11:58pm

FORCE Conference

Eva Moon, a writer, musician and performing artist, discusses her genetic mutation and how it changed the direction of her life.

July 15th 2018, 8:07pm

National Ovarian Cancer Coalition National Conference

Audra Moran, president and CEO of the Ovarian Cancer Research Fund Alliance, discusses the support available for caregivers of women with ovarian cancer.

July 15th 2018, 7:54pm

National Ovarian Cancer Coalition National Conference

Investigators are learning how to take a tumor biopsy from a patient, grow small tumors called organoids in the lab, and test cancer treatments on them to see which work best.

July 15th 2018, 7:49pm

National Ovarian Cancer Coalition National Conference

Thanks to targeted drugs and evolving research, women who experience recurrences of ovarian cancer have more treatment options than they did in the past..

July 15th 2018, 12:29am

National Ovarian Cancer Coalition National Conference

Saketh Guntupalli, M.D., gynecologic oncologist at the University of Colorado Hospital, discusses ways that women can improve intimacy after an ovarian cancer diagnosis.

July 15th 2018, 12:03am

National Ovarian Cancer Coalition National Conference

The first thing a woman should do after receiving a diagnosis of ovarian cancer, according to Teresa P. Díaz-Montes, M.D., M.P.H., is nothing. At least not right away.

July 14th 2018, 11:56pm

National Ovarian Cancer Coalition National Conference

New treatments are continually being explored as researchers use genetic testing and genomic sequencing to better understand characteristics of ovarian cancer that can be targeted with drugs.

June 11th 2018, 7:46pm

ASCO Annual Meeting

The survey contained questions on a range of issues they may have experienced, including pain, fatigue, as well as issues with sexual function, body image and finances. Researchers then looked at the anxiety and depression associated with those issues, and talked with patients about what they thought might be causing those problems.

June 5th 2018, 12:34am

ASCO Annual Meeting

Enfortumab vedotin may be a potential novel therapy for patients with locally advanced or metastatic urothelial cancer, according to updated phase 1 study findings presented during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.